The role of 5-fluorouracil (5-FU) reintroduction with irinotecan or oxaliplatin in truly 5-FU-refractory advanced colorectal cancer patients

Oncology

Volumn 68, Issue 2-3, 2005, Pages 212-216

  Scartozzi, M ^a   Sobrero, A ^b   Gasparini, G ^c   Berardi, R ^a   Catalano, V ^d   Graziano, F ^e   Barni, S ^f   Zaniboni, A ^g   Beretta, G D ^h   Labianca, R ^h   Cascinu, S ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c SAN FILIPPO NERI HOSPITAL   (Italy)

^d SAN SALVATORE HOSPITAL   (Italy)

^e Ospedale di Urbino   (Italy)

^f Azienda Ospedaliera di Treviglio   (Italy)

^g Oncologia Medica   (Italy)

^h OSPEDALI RIUNITI   (Italy)

Author keywords

5 Fluorouracil; Colorectal cancer; Second line chemotherapy

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; CAMPTOTHECIN; DRUG DERIVATIVE; PLATINUM COMPLEX;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; COLORECTAL CANCER; DATA ANALYSIS; DISEASE COURSE; DRUG ACTIVITY; DRUG INFUSION; DRUG RESPONSE; EVALUATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; COLORECTAL TUMOR; DRUG ADMINISTRATION; DRUG RESISTANCE; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 23844537616     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000086776     Document Type: Article

References (22)

1. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000;343:905-914.
2. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 2000;355:1041-1047.
3. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-2947.
4. Rougier P, Lepille D, Bennouna J, Marre A, Ducreux M, Mignot L, Hua A, Mery-Mignard D: Antitumour activity of three second-line treatment combinations in patients with metastatic colorectal cancer after optimal 5-FU regimen failure: A randomised, multicentre phase II study. Ann Oncol 2002;13:1558-1567.
5. de Gramont A, Bosset JF, Milan C, Rougier P, Bouche O, Etienne PL, Morvan F, Louvet C, Guillot T, Francois E, Bedenne L: Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French intergroup study. J Clin Oncol 1997;15:808-815.
6. Goldberg RM: Is repeated treatment with a 5-fluorouracil-based regimen useful in colorectal cancer? Semin Oncol 1998;5:21-28.
7. Hatfield AK, Goldberg RM, O'Connell MJ, Mahoney M, Krook JE: Salvage 5-FU-based chemotherapy (CT) for patients (pts) for advanced colorectal cancer (CRC) who have relapsed following surgical adjuvant (ADJ) CT: A North Central Cancer Treatment Group trial (abstract). Proc Am Soc Clin Oncol 1997;16:271a.
8. Hejna M, Kornek GV, Raderer M, Depisch D, Brodowicz T, Fiebiger WC, Scheithauer W: Reinduction therapy with the same cytostatic regimen in patients with advanced colorectal cancer. Br J Cancer 1998;78:760-764.
9. Lokich J, Fine N, Perri J, Bothe A Jr: Protracted ambulatory venous infusion of 5-fluorouracil. Am J Clin Oncol 1983;6:103-107.
10. Hansen R, Quebbeman E, Ausman R, Frick J, Ritch P, Schulte W, Haas C, Beatty P, Anderson T: Continuous systemic 5-fluorouracil infusion in advanced colorectal cancer: Results in 91 patients. J Surg Oncol 1989;40:177-181.
11. Chau I, Webb A, Cunningham D, Hill M, Waters JS, Norman A, Massey A: Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer. Br J Cancer 2001;85:1258-1264.
12. Andre T, Figer A, Cervantes A, Lledo G, Flesch M, Maindrault-Goebel F, Mineur L, Russ G, Buyse M, De Gramont A: FOLFOX7 compared to FOLFOX4. Preliminary results of the randomized optimox study (abstract). Proc Am Soc Clin Oncol 2003;22:253.
13. Rothenberg ML, Oza AM, Bigelow RH, Berlin JD, Marshall JL, Ramanathan RK, Hart LL, Gupta S, Garay CA, Burger BG, Le Bail N, Haller DG: Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: Interim results of a phase III trial. J Clin Oncol 2003;21:2059-2069.
14. Lokich J, Bothe A, Fine N, Perri J: Phase I study of protracted venous infusion of 5-fluorouracil. Cancer 1981;48:2565-2568.
15. Ardalan B, Singh G, Silberman H: A randomized phase I and II study of short term infusion of high dose fluorouracil with or without N-(phosphonacetyl)-L-aspartic acid in patients with advanced pancreatic and colorectal cancers. J Clin Oncol 1988;6:1053-1058.
16. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-216.
17. Misset JL, Bleiberg H, Sutherland W, Bekradda M, Cvitkovic E: Oxaliplatin clinical activity: A review. Crit Rev Oncol Hematol 2000;35:75-93.
18. Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C, de Gramont A: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GER-COR study. J Clin Oncol 2004;15:229-237.
19. Andre T, Louvet C, Maindrault-Goebel F, Couteau C, Mabro M, Lotz JP, Gilles-Amar V, Krulik M, Carola E, Izrael V, de Gramont A: CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GER-COR. Eur J Cancer 1999;35:1343-1347.
20. Vanhoefer U, Harstrick A, Achterrath W, Cao S, Seeber S, Rustum YM: Irinotecan in the treatment of colorectal cancer: Clinical overview. J Clin Oncol 2001;19:1501-1518.
21. Guichard S, Hennebelle I, Bugat R, Canal P: Cellular interactions of 5-fluorouracil and the camptothecin analogue CPT-11 (irinotecan) in a human colorectal carcinoma cell line. Biochem Pharmacol 1998;55:667-676.
22. Raymond E, Buquet-Fagot C, Djelloul S, Mester J, Cvitkovic E, Allain P, Louvet C, Gespach C: Antitumour activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast, and ovarian cancer. Anticancer Drugs 1997;8:876-885.